Despite rapid advances in medical technology, cancer, dementia, Parkinson's disease, diabetes, and hypertension remain challenges to overcome in an aging society.
De plus, developing a single global new drug requires an average of more than 10 years and enormous investissement costs of over KRW 1 trillion. Despite this, the success rate is extremely low.
To overcome this situation, the Ministère de SMEs and Startups has récemment moved to strengthen développement de nouveaux médicaments compétitivité by creating an écosystème in which large corporations can commercialize substance candidates developed by national startup ventures. The ministry also plans to further strengthen support for early-stage startups in the pre-IND candidate discovery phase.
An official from the Korea Institute of Toxicology, which is promoting this project, a déclaré : "The rewards for success in développement de nouveaux médicaments are enormous, but the possibility of failure is very high, so the key is identifying and supporting pre-startup candidates with technological capabilities," adding, "Prioritized support is needed for pre-candidate and pre-clinical R&D."
RudaCure has gained attention for its independently developed traitement de la sécheresse oculaire substance candidate. L'entreprise is working toward clinical advancement in Korea and abroad, with a focus on developing treatments for intractable troubles sensoriels tels que sécheresse oculaire and pain.